BeOne Medicines (BEIGF) EBT Growth (3y) (2018 - 2026)
Powered by 
Analysis
BeOne Medicines (BEIGF) EBT Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 2.28% |
| 2 | AbbVie | 442.18 Bn | 435.61 Bn | 12.70 Bn | 17.91% |
| 3 | Merck | 366.59 Bn | 359.45 Bn | 12.21 Bn | 49.60% |
| 4 | Novartis Ag | 266.49 Bn | 258.80 Bn | 11.24 Bn | 16.87% |
| 5 | Pfizer | 159.09 Bn | 147.39 Bn | 10.94 Bn | -31.77% |
| 6 | Sanofi | 52.34 Bn | 44.96 Bn | 10.79 Bn | -11.68% |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 39.37% |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | 3.60% |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn | 41.79% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 41.79% |
| Mar 31, 2026 | 40.43% |
| Dec 31, 2025 | 32.88% |
| Sep 30, 2025 | 31.37% |
| Jun 30, 2025 | 29.63% |
| Mar 31, 2025 | 27.03% |
| Dec 31, 2024 | 47.41% |
| Sep 30, 2024 | 39.00% |
| Jun 30, 2024 | 39.59% |
| Mar 31, 2024 | -81.05% |
| Dec 31, 2023 | 10.05% |
| Sep 30, 2023 | 36.21% |
| Jun 30, 2023 | -2.85% |
| Mar 31, 2023 | 2.49% |
| Dec 31, 2022 | -4.25% |
| Sep 30, 2022 | -20.91% |
| Jun 30, 2022 | -88.07% |
| Mar 31, 2022 | -35.98% |
| Dec 31, 2021 | -28.70% |
| Sep 30, 2021 | -44.02% |